These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 31387179)
1. Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer. Liu D; Cao Z; Xu W; Lin G; Zhou X; Ding X; Wang N; Wu C; Su B Biomed Pharmacother; 2019 Sep; 117():109185. PubMed ID: 31387179 [TBL] [Abstract][Full Text] [Related]
2. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Murphy M; Stordal B Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938 [TBL] [Abstract][Full Text] [Related]
3. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374 [TBL] [Abstract][Full Text] [Related]
4. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer. Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272 [TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib. Wang J; Wang Y; Zheng C; Hou K; Zhang T; Qu X; Liu Y; Kang J; Hu X; Che X Cell Biol Int; 2018 Sep; 42(10):1292-1299. PubMed ID: 29885023 [TBL] [Abstract][Full Text] [Related]
6. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. Lee CK; Brown C; Gralla RJ; Hirsh V; Thongprasert S; Tsai CM; Tan EH; Ho JC; Chu da T; Zaatar A; Osorio Sanchez JA; Vu VV; Au JS; Inoue A; Lee SM; Gebski V; Yang JC J Natl Cancer Inst; 2013 May; 105(9):595-605. PubMed ID: 23594426 [TBL] [Abstract][Full Text] [Related]
7. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Wu M; Yuan Y; Pan YY; Zhang Y Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891 [TBL] [Abstract][Full Text] [Related]
8. Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer. Huang HN; Hung PF; Chen YP; Lee CH Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338651 [TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Peled N; Wynes MW; Ikeda N; Ohira T; Yoshida K; Qian J; Ilouze M; Brenner R; Kato Y; Mascaux C; Hirsch FR Cell Oncol (Dordr); 2013 Jul; 36(4):277-88. PubMed ID: 23619944 [TBL] [Abstract][Full Text] [Related]
10. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations. Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945 [TBL] [Abstract][Full Text] [Related]
11. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210 [TBL] [Abstract][Full Text] [Related]
12. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2. Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477 [TBL] [Abstract][Full Text] [Related]
13. Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer. Tang C; Gao H; Li X; Liu Y; Li J; Qin H; Wang W; Qu L; An J; Yang S; Liu X J Cancer Res Clin Oncol; 2014 Mar; 140(3):427-33. PubMed ID: 24401995 [TBL] [Abstract][Full Text] [Related]
14. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer. Fu Y; Zhang Y; Lei Z; Liu T; Cai T; Wang A; Du W; Zeng Y; Zhu J; Liu Z; Huang JA J Hematol Oncol; 2020 Dec; 13(1):169. PubMed ID: 33287873 [TBL] [Abstract][Full Text] [Related]
15. Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis. Xiang M; Jiang HG; Shu Y; Chen YJ; Jin J; Zhu YM; Li MY; Wu JN; Li J Int J Biol Sci; 2020; 16(9):1536-1550. PubMed ID: 32226300 [TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer. Pan H; Jiang T; Cheng N; Wang Q; Ren S; Li X; Zhao C; Zhang L; Cai W; Zhou C Oncotarget; 2016 Aug; 7(31):49948-49960. PubMed ID: 27409677 [TBL] [Abstract][Full Text] [Related]
17. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357 [TBL] [Abstract][Full Text] [Related]
18. A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation. Zhang L; Qi Y; Xing K; Qian S; Zhang P; Wu X Oncol Rep; 2018 Aug; 40(2):1046-1054. PubMed ID: 29917169 [TBL] [Abstract][Full Text] [Related]
19. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells. Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949 [TBL] [Abstract][Full Text] [Related]
20. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Sun X; Xu Y; Wang Y; Chen Q; Liu L; Bao Y Med Sci Monit; 2018 May; 24():3193-3203. PubMed ID: 29763936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]